Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Dimebon for Alzheimer's disease

Esta versión no es la más reciente

ver la versión actual 21 abril 2015

Información

DOI:
https://doi.org/10.1002/14651858.CD009524Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 07 diciembre 2011see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Demencia y trastornos cognitivos

Copyright:
  1. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Nathan Herrmann

    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

  • Sarah Chau

    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

  • Julia M Hussman

    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

  • Krista L Lanctôt

    Correspondencia a: Sunnybrook Research Institute, Senior Scientist, Brain Sciences Program, Executive Director of MORE Resarch Group, Toronto, Canada

    [email protected]

Declarations of interest

KLL is the executive director of the Medical Outcomes and Research in Economics (MORE) Research group, receives research funding from Abbott Laboratories, Sonexa Therapeutics Inc., Workers Safety and Insurance Board (WSIB) and Lundbeck Canada, is funded by grants from the National Institute of Health, Canadian Institute of Health Research, the Alzheimer's Society of Canada, the Ontario Mental Health Foundation, the Heart and Stroke Foundation and Physician's Services Incorporated Foundation.

NH receives research funding from Sonexa Therapeutics Inc. and Lundbeck Canada Inc., and holds grants from the National Institute of Health, the Ontario Mental Health Foundation, the Canadian Institute of Health Research, Alzheimer's Society of Canada, Heart and Stroke Foundation, and Physicians’ Services Incorporated Foundation. NH receives speaker's honoraria from Lundbeck, Pfizer, Janssen Ortho and Novartis, and has participated in an advisory board meeting for Pfizer regarding Latriperdine.

Version history

Published

Title

Stage

Authors

Version

2015 Apr 21

Latrepirdine for Alzheimer's disease

Review

Sarah Chau, Nathan Herrmann, Myuri T Ruthirakuhan, Jinghan Jenny Chen, Krista L Lanctôt

https://doi.org/10.1002/14651858.CD009524.pub2

2011 Dec 07

Dimebon for Alzheimer's disease

Protocol

Nathan Herrmann, Sarah Chau, Julia M Hussman, Krista L Lanctôt

https://doi.org/10.1002/14651858.CD009524

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Table 1. Search strategy for MEDLINE

Source

Search Strategy

Medline (Ovid SP)

1.      latriperdine.mp.

2.      dimebon.mp.

3.      dimebolin.mp.

4.      2,3,4,5‐tetrahydro‐2,8‐dimethyl‐5‐(2‐(6‐methyl‐3‐pyridyl)ethyl)‐1H‐pyrido(4,3‐b)indole.mp.

5.      (1 OR 2 OR 3 OR 4)

6.      (Alzheimer* OR AD).mp.

7.      Alzheimer Disease/

8.      Dement*.mp.

9.      (6 OR 7 OR 8)

10.    (5 AND 9)

11.    randomized controlled trial.pt.

12.    controlled clinical trial.pt.

13.    randomized.ab.

14.    "randomized controlled trial".tw.

15.    placebo.ab.

16.    drug therapy.fs.

17.    randomly.ab.

18.    trial.ab.

19.    groups.ab.

20.    (11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19)

21.    humans.sh.

22.    (20 AND 21)

23. (10 AND 22)
Figuras y tablas -
Table 1. Search strategy for MEDLINE
Ir a la tabla del protocolo